Ken Griffin
APGN

Ken Griffin’s Apexigen, Inc. Common Stock APGN Stock Holding History

Ken Griffin’s Portfolio APGN Stock Details APGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25,624
Closed -$17.7K – 15904
2022
Q4 		$17.7K Sell
25,624
-26,766
-51% -$52.2K ﹤0.01% 13233
2022
Q3 		$141K Buy
+52,390
New +$426K ﹤0.01% 10782

Other funds holding APGN

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80B AUM 26.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Ken Griffin's APGN Position: Q1 2023 in Review

Ken Griffin sold out of Apexigen, Inc. Common Stock (APGN) in Q1 2023, closing a stake of 25,624 shares — an estimated $17.7K sold.

Ken Griffin first reported a position in APGN in Q3 2022 and held it in 2 quarters. The position peaked at $141K in Q3 2022. 20 funds tracked by Wall St. Rank hold APGN as of Q1 2023.

  • Ken Griffin reported no remaining Apexigen, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Ken Griffin sold 25,624 Apexigen, Inc. Common Stock shares in Q1 2023, an estimated $17.7K.
  • Ken Griffin first reported a position in Apexigen, Inc. Common Stock in Q3 2022 and held it in 2 quarters.
  • Ken Griffin's Apexigen, Inc. Common Stock position peaked at $141K in Q3 2022.
  • 20 funds tracked by Wall St. Rank held Apexigen, Inc. Common Stock as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.